Market News AIOpen the app

ARWR stock news · Arrowhead Pharmaceuticals, Inc.

Stories about Arrowhead Pharmaceuticals, Inc. (ARWR) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ARWR

Follow Arrowhead Pharmaceuticals, Inc. (ARWR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ARWR
Free on the App Store and Google Play, or on the web.
  1. Nov 12, 2026, 4:05 PM ET · Market

    Arrowhead Pharmaceuticals shared its financial results for the year ending September 30, 2026, and will hold a call to discuss them.

    Good for ARWR

    Arrowhead reported that new REDEMPLO prescriptions rose 63% quarter over quarter, with U.S. coverage reaching 160 million lives. Growing use and wider access point to a stronger business outlook, though a larger use still needs FDA approval.

  2. Oct 14, 2026, 1:34 PM ET · Market

    Arrowhead Pharmaceuticals is moving forward with its Alzheimer's drug after seeing encouraging early test results.

    Good for ARWR

    Arrowhead reported lasting tau reductions and mostly mild side effects in healthy volunteers. These early results support its Alzheimer's drug program, though patient benefits remain untested.